DelveInsight’s “Cystinosis Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Cystinosis pipeline landscapes. It comprises Cystinosis pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Cystinosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Cystinosis pipeline products.
Some of the key takeaways of the Cystinosis Pipeline Report:
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, etc., are developing therapies for the treatment of Cystinosis.
Emerging therapies such as Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), are expected to have a significant impact on the Cystinosis market in the coming years.
ELX-02 (formerly known as NB124) is a small molecule, administered by the parenteral subcutaneous (SC) route. The molecule is under investigation for the treatment of cystinosis. It is under Phase II clinical trial.
Get an overview of pipeline landscape @ Cystinosis Clinical Trials Analysis
Cystinosis is a lysosomal storage disease characterized by the abnormal accumulation of cystine, the oxidized dimer of the amino acid cysteine. It is a genetic disorder that follows an autosomal recessive inheritance pattern.
For further information, refer to the detailed report @ Cystinosis Pipeline Therapeutics
Cystinosis Emerging Drugs
Procysbi (cysteamine bitartrate) by Horizon Pharma
Cystadrops (cysteamine hydrochloride) by Recordati S.p.A.
Cystaran (cysteamine hydrochloride) by Leadiant Biosciences
Cystagon (cysteamine bitartrate) by Mylan Pharmaceuticals
Scope of Cystinosis Pipeline Drug Insight
Coverage: Global
Major Players: Horizon Pharma, Recordati S.p.A., Leadiant Biosciences, Mylan Pharmaceuticals, and others.
Pipeline Therapies: Procysbi (cysteamine bitartrate), Cystadrops (cysteamine hydrochloride), Cystaran (cysteamine hydrochloride), Cystagon (cysteamine bitartrate), and others.
Table of Contents
1
Cystinosis Report Introduction
2
Cystinosis Executive Summary
3
Cystinosis Overview
4
Cystinosis- Analytical Perspective In-depth Commercial Assessment
5
Cystinosis Pipeline Therapeutics
6
Cystinosis Late Stage Products (Phase II/III)
7
Cystinosis Mid Stage Products (Phase II)
8
Cystinosis Early Stage Products (Phase I)
9
Cystinosis Preclinical Stage Products
10
Cystinosis Therapeutics Assessment
11
Cystinosis Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Cystinosis Key Companies
14
Cystinosis Key Products
15
Cystinosis Unmet Needs
16
Cystinosis Market Drivers and Barriers
17
Cystinosis Future Perspectives and Conclusion
18
Cystinosis Analyst Views
19
Appendix
20
About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/